Question 1

What is Basilea Pharmaceutica?

Accepted Answer

Basilea Pharmaceutica is a Company.

Question 2

How often does Basilea Pharmaceutica appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 13 articles.

Question 3

When was Basilea Pharmaceutica first tracked by NewsDesk?

Accepted Answer

First tracked on May 27, 2026.

Question 4

When was Basilea Pharmaceutica last mentioned in news?

Accepted Answer

Last active on Jun 01, 2026.

Question 5

What is Basilea Pharmaceutica's current news sentiment?

Accepted Answer

Aggregate sentiment score: 35 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Basilea Pharmaceutica in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Basilea Pharmaceutica?

Accepted Answer

Basilea receives BARDA funding (May 27, 2026, 7 articles).

Question 8

How did the "Basilea receives BARDA funding" event impact Basilea Pharmaceutica?

Accepted Answer

Basilea Pharmaceutica received USD 13.3 million in funding from United States — Biomedical Advanced Research and Development Authority>>> to continue the development of its novel antibiotic, ceftibuten-ledaborbactam etzadroxil. This funding supports the advancement of its clinical phase 3 program, addressing a critical unmet need for oral treatment of complicated urinary tract infections.

Question 9

How did the "Innoviva to Attend Investor Conferences" event impact Basilea Pharmaceutica?

Accepted Answer

Basilea Pharmaceutica is the licensor of ZEVTERA to Innoviva.

Question 10

How is this data collected?

Accepted Answer

NewsDesk aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.